Compare Hormel Foods Corp (HRL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Viatris Inc — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while Viatris Inc trades at $17.39 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Viatris Inc for 57 Days on average.
| HRL | VTRS | |
|---|---|---|
Market Cap | $10.69B | $20.03B |
Volume | 10,041,387 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $18.27 |
52-Week Low | $19.42 | $9.74 |
Typical Hold Time | 99 Days | 57 Days |
Enterprise Value | $12.67B | $32.15B |
Dividend Yield | 6.02% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.55, down 1.66% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, while recent quarterly earnings have consistently beaten expectations. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, though cash flow trends show volatility with 2025 net cash flow negative $71M.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 24% upside. Key risks include declining profit margins, high payout ratios, and integration challenges from recent acquisition. The 60-year dividend streak provides stability but raises sustainability concerns amid shrinking raises.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
